Staphylococcus aureus infections are obviously a huge topic. We broke up the literature into the categories of “bacteremia” and “everything else” to make it easier to keep track of all of the resources. This collection was compiled by @DrH_flu and others. Please let us know if there are more papers that you think merit being listed here as “must read” papers for ID fellows.
Staphylococcus aureus Bacteremia
- Beta-lactam + vanc or dapto combination therapy for MRSAB: shortens bacteremia but doesn’t improve mortality; dapto + BL combo might improve mortality
- Wang et al. Antimicrob Agents Chemother. 2020;64(11):e01377-20.
- https://doi.org/10.1128/AAC.01377-20
- Meta-analysis: comparison of mortality between MSSAB and MRSAB
- Cosgrove et al. Clin Infect Dis. 2003;36:53-59.
- https://doi.org/10.1086/345476
- Meta-analysis: short-course therapy for catheter-related SAB
- Jernigan et al. Ann Intern Med. 193;119:304-311.
- https://doi.org/10.7326/0003-4819-119-4-199308150-00010
- Criteria for identifying SAB at low risk for endocarditis
- Heriot et al. Open Forum Infect Dis. 2017;4:ofx261.
- https://doi.org/10.1093/ofid/ofx261
- Cefazolin > anti-staph PCNs for MSSAB
- Shi et al. BMC Infect Dis. 2018;18:508.
- https://doi.org/10.1186/s12879-018-3418-9
- MA: cefazolin > anti-staph PCNs for MSSAB
- Bidell et al. J Antimicrob Chemother. 2018.
- https://doi.org/10.1093/jac/dky259
- MA: cefazolin > anti-staph PCNs for MSSAB
- Rindone et al. Br J Clin Pharmacol. 2018;84:1258-1266.
- https://doi.org/10.1111/bcp.13554
- The significance of vancomycin MIC in S. aureus infections: higher = greater mortality
- van Hal et al. Clin Infect Dis. 2012;54(6):755-771.
- https://doi.org/10.1093/cid/cir935
- Characteristics of SAB and risks of mortality
- Kaasch et al. J Infect. 2014;68(3):242-251.
- https://doi.org/10.1016/j.jinf.2013.10.015
- Cefazolin vs. PCNs for MSSAB
- Weis et al. Clin Microbiol Infect. 2019;25(7):818-827
- https://doi.org/10.1016/j.cmi.2019.03.010
- Linezolid PO was noninferior to vancomycin for treatment of MRSAB
- Shorr et al. J Antimicrob Chemother. 2005;56(5):923-929.
- https://doi.org/10.1093/jac/dki355
- Management of SAB and endocarditis: progress and challenges
- Kern. Curr Opin Infect Dis. 2010;23(4):346-358.
- https://doi.org/10.1097/QCO.0b013e32833bcc8a
- Management of SAB
- Thwaites et al. Lancet Infect Dis. 2011;11:208-222.
- https://doi.org/10.1016/S1473-3099(10)70285-1
- Management of SAB
- Holland et al. J Am Med Assoc 2014;312(13):1330.1341.
- https://doi.org/10.1001/jama.2014.9743
- Daptomycin in combination with other antibiotics for MRSAB
- Dhand et al. Clin Ther. 2014;36:1303-1316.
- https://doi.org/10.1016/j.clinthera.2014.09.005
- MRSAB salvage therapy
- Kullar et al. J Antimicrob Chemother. 2016;71:576-586.
- https://doi.org/10.1093/jac/dkv368
- SAB and IE epidemiology and outcome
- Asgeirsson et al. Infect Dis (Lond). 2018;50(3):175-192.
- https://doi.org/10.1080/23744235.2017.1392039
- Empirical use of vanc + beta-lactam for SAB
- McConeghy et al. Clin Infect Dis. 2013;57(12):1760-1765.
- https://doi.org/10.1093/cid/cit560
- Reconsider 7-day threshold for “persistent” SAB
- Kullar et al. Clin Infect Dis. 2014;59(10):1455-1461.
- https://doi.org/10.1093/cid/ciu583
- MIC creep and daptomycin nonsusceptibility
- Moise et al. Lancet Infect Dis. 2009;9(10):617-624.
- https://doi.org/10.1016/S1473-3099(09)70200-2
- Resurrecting beta-lactams for use in MRSAB
- Foster. Trends Microbiol. 2019;27(1):26-38.
- https://doi.org/10.1016/j.tim.2018.06.005
- Delay in antibiotics in hospital-acquired SAB increased the risk of mortality and increased length of stay
- Lodise et al. Clin Infect Dis. 2003;36(11):1418-1423.
- https://doi.org/10.1086/375057
- Daptomycin was noninferior to beta-lactam or vancomycin + gentamicin for SAB/IE
- Fowler et al. N Engl J Med. 2006;355(7):653-665.
- https://doi.org/10.1056/NEJMoa053783
- Higher MIC to vancomycin was associated with higher mortality for both MSSAB and MRSAB
- Holmes et al. J Infect Dis. 2011;204(3):340-347.
- https://doi.org/10.1093/infdis/jir270
- Higher MIC to vancomycin was associated with higher mortality for both MSSA IE and MRSA IE
- Cervera et al. Clin Infect Dis. 2014;58(12):1668-1675.
- https://doi.org/10.1093/cid/ciu183
- Early valve surgery was not associated with lower mortality rate in patients with S. aureus PVIE
- Chirouze et al. Clin Infect Dis. 2015;60(5):741-749.
- https://doi.org/10.1093/cid/ciu871
- The longer the bacteremia, the higher the mortality. Delay in source control led to increased mortality
- Minejima et al. Clin Infect Dis. 2020;70(4):566-573.
- https://doi.org/10.1093/cid/ciz257
- Methicillin resistance did not increase the risk of mortality. Delineation of high, medium, and low risk categories
- Soriano et al. Clin Infect Dis. 2000;31(2):368-373.
- https://doi.org/10.1086/313650
- Increased mortality with uneradicated focus of infection and inadequate antibiotic dosing
- Jensen et al. Arch Intern Med. 2002;162(1):25-32.
- https://doi.org/10.1001/archinte.162.1.25
- Outcomes in catheter-associated SAB; low-risk
- Thomas et al. Intern Med J. 2005;35:319-330.
- https://doi.org/10.1111/j.1445-5994.2005.00823.x
- Risk factors for recurrence in SAB
- Kreisel et al. Diagn Microbiol Infect Dis. 2006;55(3):179-84.
- https://doi.org/10.1016/j.diagmicrobio.2006.01.021
- Adherence to guidelines decreases 30-day mortality
- Nagao et al. Clin Microbiol Infect 2010; 16:1783–8.
- https://doi.org/10.1111/j.1469-0691.2010.03156.x
- Mortality rates with MRSA can be as high as 57%
- Lamagni et al. J Hosp Infect. 2011;77(1):16-20.
- https://doi.org/10.1016/j.jhin.2010.07.015
- MRSA was independently associated with almost 50% higher likelihood of hospital mortality compared with MSSA
- Hanberger et al. Int J Antimicrob Agents. 2011;38:331-335.
- https://doi.org/10.1016/j.ijantimicag.2011.05.013
- Predictors of mortality in SAB
- van Hal et al. Clin Microbiol Rev. 2012;25:362-386.
- https://doi.org/10.1128/CMR.05022-11
- Risk factors for long-term mortality after SAB
- Yahav et al. Eur J Clin Microbiol Infect Dis. 2016;35(5):785-90.
- https://doi.org/10.1007/s10096-016-2598-8
- Patients with CHF had higher mortality from SAB than controls
- Smit et al. BMC Infect Dis. 2016;16:227.
- https://doi.org/10.1186/s12879-016-1570-7
- Predictors of early and late mortality in SAB
- Bassetti et al. PLoS One. 2017;12:e0170236.
- https://doi.org/10.1371/journal.pone.0170236
- Risk factors for 30-day mortality in SAB
- Ayau et al. Int J Infect Dis. 2017;61:3-6.
- https://doi.org/10.1016/j.ijid.2017.05.010
- Adherence to guidelines decreases 30-day mortality
- Nagao et al. Infection 2017; 45:83–91.
- https://doi.org/10.1007/s15010-016-0946-3
- Need for TEE in SAB
- Wong. Eur J Clin Microbiol Infect Dis. 2014 Nov;33(11):2053-9.
- https://doi.org/10.1007/s10096-014-2178-8
- Echo has minimal yield in SAB without clinical risk factors for IE
- Heriot et al. Eur J Clin Microb Infect Dis. 2015;34:1231-1236.
- https://doi.org/10.1007/s10096-015-2352-7
- Echo is dispensible in low-risk SAB
- Khatib et al. Medicine 2013;92:182-188.
- https://doi.org/10.1097/MD.0b013e318294a710
- Echo in SAB at low risk of IE
- Heriot et al. Open Forum Infect Dis. 2018;5:ofy303.
- https://doi.org/10.1093/ofid/ofy303
- Criteria for guiding echo use in nosocomial SAB
- Kaasch et al. Clin Infect Dis 2011;53:1-9.
- https://doi.org/10.1093/cid/cir320
- Nafcillin was superior to vancomycin for SAB
- Chang et al. Medicine (Baltimore). 2003;82(5):333-339.
- https://doi.org/10.1097/01.md.0000091184.93122.09
- In MSSAB, risk of death at 30 days is lower with beta-lactam therapy than with vancomycin
- McDanel et al. Clin Infect Dis. 2015;61(3):361-367.
- https://doi.org/10.1093/cid/civ308
- Vancomycin was worse than cefazolin in HD patients with MSSAB
- Stryjewski et al. Clin Infect Dis. 2007;44(2):190-6.
- https://doi.org/10.1086/510386
- Lower mortality after receiving beta-lactam vs. vancomycin in MSSAB
- Schweizer et al. BMC Infect Dis. 2011;11:279.
- https://doi.org/10.1186/1471-2334-11-279
- Cefuroxime was better than PCN or dicloxacillin for PSSAB
- Nissen et al. J Antimicrob Chemother. 2013;68(8):1894-1900.
- https://doi.org/10.1093/jac/dkt108
- Patients with MSSAB will have inferior outcomes with vancomycin instead of having their PCN allergy evaluated
- Blumenthal et al. Clin Infect Dis. 2015;61:741-749.
- https://doi.org/10.1093/cid/civ394
- Beta-lactam therapy is better than vancomycin for MSSAB
- Wong et al. Ann Clin Microbiol Antimicrob. 2016;15:27.
- https://doi.org/10.1186/s12941-016-0143-3
- Are all beta-lactams similarly effective in the treatment of MSSAB? cefazolin or cloxacillin were the best
- Paul et al. Clin Microbiol Infect. 2011 Oct;17(10):1581-6.
- https://doi.org/10.1111/j.1469-0691.2010.03425.x
- Inoculum effect of cefazolin didn’t matter
- Nannini et al. Antimicrob Agents Chemother. 2009;53:3437-3441.
- https://doi.org/10.1128/AAC.00317-09
- Inoculum effect of cefazolin didn’t matter
- Chong et al. Eur J Clin Microbiol Infect Dis. 2015;34:349-355.
- https://doi.org/10.1007/s10096-014-2241-5
- Inoculum effect of cefazolin didn’t matter
- Lee et al. Microb Drug Resist. 2014;20;568-574.
- https://doi.org/10.1089/mdr.2013.0229
- Inoculum effect of cefazolin DID matter
- Lee et al. Clin Microbiol Infect. 2018;24:152-158.
- https://doi.org/10.1016/j.cmi.2017.07.001
- Ceftriaxone is bad for MSSA
- Carr et al. Open Forum Infect Dis. 2018;5(5):ofy089.
- https://doi.org/10.1093/ofid/ofy089
- Ceftriaxone was ok for MSSAB on OPAT
- Hamad et al. Open Forum Infect Dis. 2020;7(9):ofaa341.
- https://doi.org/10.1093/ofid/ofaa341
- Daptomycin had better outcomes in MRSAB with higher vancomycin MICs but still had clinical failures
- Moore et al. Clin Infect Dis. 2012;54(1):51-58.
- https://doi.org/10.1093/cid/cir764
- Daptomycin and vancomycin had similar outcomes in MRSAB with vancomycin MICs >1 but both had 35% failure rate
- Moise et al. Clin Ther. 2016;38(1):16-30.
- https://doi.org/10.1016/j.clinthera.2015.09.017
- Use of gentamicin combination for IE (case report)
- Murray et al. Arch Intern Med. 1976;136(4):480-483.
- https://doi.org/10.1001/archinte.1976.03630040082017
- Gentamicin for native valve IE due to Staph is nephrotoxic and shouldn’t be used
- Cosgrove et al. Clin Infect Dis. 2009;48(6):713-721.
- https://doi.org/10.1086/597031
- Adding rifampin to vancomycin for MRSA IE didn’t improve outcomes
- Levine et al. Ann Intern Med. 1991;115(9):674-680.
- https://doi.org/10.7326/0003-4819-115-9-674
- Adding rifampin to treatment for SA native valve IE isn’t worth it due to hepatotoxicity and DDIs
- Riedel et al. Antimicrob Agents Chemother. 2008;52(7):2463-2467.
- https://doi.org/10.1128/AAC.00300-08
- Vancomyin and others reduced methicillin resistance in vitro
- Sieradzki et al. J Antimicrob Chemother. 1997;39(Suppl A):47–51.
- https://doi.org/10.1093/jac/39.suppl_1.47
- Cefazolin and vancomycin synergy in vitro
- Hagihara et al. Antimicrob Agents Chemother. 2012;56(1):202–207.
- https://doi.org/10.1128/AAC.05473-11
- Beta-lactam and daptomycin synergy in vitro
- Mehta et al. Antimicrob Agents Chemother. 2012;56:6192-6200.
- https://doi.org/10.1128/AAC.01525-12
- Daptomycin synergy in vitro
- Berti et al. Antimicrob Agents Chemother. 2012;56:5046-5053.
- https://doi.org/10.1128/AAC.00502-12
- Seesaw effect
- Ortwine et al. Drug Resist Updat. 2013;16:73-79.
- https://doi.org/10.1016/j.drup.2013.10.002
- Seesaw effect
- Werth et al. Antimicrob Agents Chemother. 2013;57(1):2664-2668.
- https://doi.org/10.1128/AAC.02308-12
- Ceftaroline enhances daptomycin activity in daptomycin-nonsusceptible VISA in vitro
- Werth et al. Antimicrob Agents Chemother. 2013;57(1):66-73.
- https://doi.org/10.1128/AAC.01586-12
- Seesaw effect with vancomycin, teicoplanin, daptomycin, ceftaroline
- Barber et al. Infect Dis Ther. 2014;3:35-43.
- https://doi.org/10.1007/s40121-014-0023-0
- Vanc and ceftaroline synergy in vitro and in vivo
- Barber et al. J Antimicrob Chemother. 2015;70(2):311-313.
- https://doi.org/10.1093/jac/dku322
- Ceftaroline + daptomycin synergy in vitro
- Barber et al. J Antimicrob Chemother. 2015;70(2):505-509.
- https://doi.org/10.1093/jac/dku378
- Ceftaroline alone and in combination against MRSA in vitro
- Barber et al. Antimicrob Agents Chemother. 2015;59:4497-4503.
- https://doi.org/10.1128/AAC.00386-15
- Molecular basis of beta-lactam daptomycin synergy
- Berti et al. Antimicrob Agents Chemother. 2015;60(1):451-458.
- https://doi.org/10.1128/AAC.02071-15
- Molecular basis of seesaw effect
- Renzoni et al. Antimicrob Agents Chemother. 2016;61(1):e01634-16
- https://doi.org/10.1128/AAC.01634-16
- Beta-lactam and vancomycin synergy in vitro
- Tran et al. Antimicrob Agents Chemother. 2018;62(6):e00157-18.
- https://doi.org/10.1128/AAC.00157-18
- Case series of daptomycin + beta-lactams in refractory MRSAB
- Dhand et al. Clin Infect Dis. 2011;53(2):158-163.
- https://doi.org/10.1093/cid/cir340
- Ceftaroline + daptomycin in daptomycin-nonsusceptible MRSAB
- Rose et al. Antimicrob Agents Chemother. 2012;56:5296-5302.
- https://doi.org/10.1128/AAC.00797-12
- Daptomycin was safe and well-tolerated in SAB with mild-mod renal impairment and addition of beta-lactams enhanced treatment efficacy in some groups
- Moise et al. Antimicrob Agents Chemother. 2013;57(3):1192-200
- https://doi.org/10.1128/AAC.02192-12
- Daptomycin + ceftaroline salvage
- Sakoulas et al. Clin Ther. 2014;36:1317-1333.
- https://doi.org/10.1016/j.clinthera.2014.05.061
- Beta-lactams enhance vancomycin activity in SAB
- Dilworth et al. Antimicrob Agents Chemother. 2014;58:102-109.
- https://doi.org/10.1001/jama.2020.0103
- CAMERA trial: vanc + b-lactam may shorten duration of MRSA bacteremia
- Davis et al. Clin Infect Dis 2016;62(2):173-180.
- https://doi.org/10.1093/cid/civ808
- Vancomycin + beta-lactam retrospective analysis
- Casapao et al. Pharmacother. 2017;37:1347-1356.
- https://doi.org/10.1002/phar.2034
- Ceftaroline for MRSAB
- Zasowski et al. Antimicrob Agents Chemother.2017;61:e02015-16.
- https://doi.org/10.1128/AAC.02015-16
- Ceftaroline + daptomycin for refractory MRSAB in a child (case report)
- Hall et al. J Pediatr Pharmacol Ther. 2018;23(6):490-493.
- https://doi.org/10.5863/1551-6776-23.6.490
- Early dapto + ceftaroline shortens bacteremia
- Cortes-Penfield et al. Infect Dis (London). 2018;50(8):643-647.
- https://doi.org/10.1080/23744235.2018.1448110
- Vancomycin + beta-lactam had significantly fewer treatment failures than vancomycin monotherapy for MRSAB, no different in 30-day mortality (retrospective)
- Truong et al. Antimicrob Agents Chemother. 2018;62(2):e01554-17.
- https://doi.org/10.1128/AAC.01554-17
- Dapto + ceftaroline may have benefit over vanc monotherapy for MRSA bacteremia
- Geriak et al. Antimicrob Agents and Chemother 2019;63(5):e02483-18
- https://doi.org/10.1128/AAC.02483-18
- Dapto + ceftaroline was effective as salvage therapy and highest mortality benefit was when used within 72 hours of index culture (retrospective cohort)
- McCreary et al. Open Forum Infect Dis. 2019;7(1):ofz538.
- https://doi.org/10.1093/ofid/ofz538
- Vancomycin + cefepime resulted in faster bacterial clearance in MRSAB but no association with 30-day mortality
- Zasowski et al. Open Forum Infect Dis. 2019;6(4):ofz079.
- https://doi.org/10.1093/ofid/ofz079
- Daptomycin + beta-lactam combination therapy for MRSAB retrospective cohort study
- Jorgensen et al. Clin Infect Dis 2020;71(1):1-10.
- https://doi.org/10.1093/cid/ciz746
- Vancomycin or daptomycin + beta-lactam (any) was associated with lower 60-day recurrence but not with lower 30-day mortality
- Alosaimy et al. Infect Dis Ther. 2020;9:325-339.
- https://doi.org/10.1007/s40121-020-00292-8
- CAMERA-2 trial: combo therapy for MRSA had no benefit and increased toxicity
- Tong et al. JAMA. 2020;323(6):527-537.
- https://doi.org/10.1001/jama.2020.0103
- Duration for catheter-related SAB should be at least 10 days
- Raad et al. Clin Infect Dis. 1992;14(1):75-82.
- https://doi.org/10.1093/clinids/14.1.75
- High rate of recurrence when catheter-related SAB was treated for less than 10 days
- Malanoski et al. Arch Intern Med. 1995;155(11):1161-1166.
- https://doi.org/10.1001/archinte.155.11.1161
- Treatment courses <14 days were associated with higher mortality
- Jensen et al. Arch Intern Med. 2002;162:25–32
- https://doi.org/10.1001/archinte.162.1.25
- Treatment duration for uncomplicated SAB to prevent relapse
- Chong et al. Antimicrob Agents Chermother 2013;57:1150-1156.
- https://doi.org/10.1128/AC.01021-12
- Standard vs. prolonged course for uncomplicated SAB in hematologic malignancy
- Cheung et al. Open Forum Infect Dis. 2018;5:S320-S321.
- https://doi.org/10.1093/ofid/ofy210.908
- 14 days noninferior to >14 days for Uncomplicated SAB
- Taupin et al. Open Forum Infect Dis. 2020;7(10):
- Early switch to PO linezolid in low-risk SAB: no difference in 90-day relapse
- Willekens et al. 2019;Clin Infect Dis. 69:381-387.
- https://doi.org/10.1093/cid/ciy916
- SABATO protocol: early oral switch in low-risk SAB
- Kaasch et al. Trials 2015;16:450.
- https://doi.org/10.1186/s13063-015-0973-x
- Early switch to PO beta-lactams was safe and efficacious in selected low-risk MSSA bacteremia cases
- Bupha-Intr et al. Antimicrob Agents Chemother 2020;64:e02345-19.
- https://doi.org/10.1128/AAC.02345-19
- Oral switch = IV for SAB
- Perez-Rodriguez et al. Int J Infect Dis. 2020.
- https://doi.org/10.1016/j.ijid.2020.10.097
- Switch to oral = IV for MRSAB
- Jorgensen et al. J Antimicrob Chemother. 2019;74(2):489-498.
- https://doi.org/10.1098/jac/dky452
- In pregnant women with SAB, outcomes are poor for mother and baby
- Morelli et al. Open Forum Infect Dis. 2020;7(8):ofaa239.
- https://doi.org/10.1093/ofid/ofaa239
- Case series of cefazolin + ertapenem combination for salvage of MRSAB
- Ulloa et al. Clin Infect Dis. 2020;71(6):1413-1418.
- https://doi.org/10.1093/cid/ciz995
- Staph aureus bacteruria is associated with SAB, especially vertebral and complicated urinary infections
- Choi et al. J Infect. 2009;59(1):37-41.
- https://doi.org/10.1016/j.jinf.2009.05.002
- Thrombocytopenia in SAB is a poor prognostic factor
- Gafter-Gvili et al. Mayo Clin Proc. 2011;86:389-396.
- https://doi.org/10.4065/mcp.2010.0705
- Comment on Jorgensen et al. MRSAB combo trial
- Holland et al. Clin Infect Dis. 2020;71(1):11-13.
- https://doi-org/10.1093/cid/ciz750
Treatment of persistent bacteremia
https://twitter.com/ID_fellows/status/1292815194037661697?s=20
Chalk talk photo
https://twitter.com/jackpenner/status/1212920471810801664?s=20
Everything Else S. aureus
MRSA infections in adults and children
- Liu et al. Clin Infect Dis 2011;52:e18–e55.
- https://doi.org/10.1093/cid/ciq146
S. aureus infections
- Lowy. N Engl J Med. 1998;339(8):520-532.
- https://doi.org/10.1056/NEJM199808203390806
S. aureus comprehensive review
- Tong et al. Clin Microbiol Rev. 2015;28(3):603-661.
- https://doi.org/10.1128/CMR.00134-14
Beta-lactam therapy for MSSA; inoculum effect with cefazolin
- Li et al. Pharmacotherapy 2017;37:346-360.
- https://doi.org/10.1002/phar.1892
Beta-lactam therapy for MSSA; inoculum effect with cefazolin
- Loubet et al. Clin Microbiol Infect. 2018;24:125-132.
- https://doi.org/10.1016/j.cmi.2017.07.003
TMP-SMX for MRSA
- Grim et al. Pharmacotherapy. 2005 Feb;25(2):253-64.
- https://doi.org/10.1592/phco.25.2.253.56956
Cefazolin = anti-staph PCNs for MSSA infections
- Eljaaly et al. Antimicrob Agents Chemother. 2018;62(4):e01816-17.
- https://doi.org/10.1128/AAC.01816-17
TMP-SMX may be an effective option for severe S. aureus infections including bacteremia
- Adra et al. Ann Pharmacother. 2004;38(2):338-341.
- https://doi.org/10.1345/aph.1D156
Linezolid might be better than vancomycin for cSSTI but it’s hard to tell; more adverse events
- Bounthavong et al. Curr Med Res Opin. 2010;26(2):407-421.
- https://doi.org/10.1185/03007990903454912
Linezolid was more effective than vancomycin for cSSTI but no difference in bacteremia
- Beibei et al. Int J Antimicrob Agents. 2010;35(1):3-12.
- https://doi.org/10.1016/j.ijantimicag.2009.09.013
Linezolid was not superior but no worse than vancomycin for MRSA nosocomial pneumonia
- Wang et al. Eur J Clin Pharmacol. 2015;71(1):107-115.
- https://doi.org/10.1007/s00228-014-1775-x
SA-infected orthopedic implants with fusidic acid or oflaxacin + rifampin
- Drancourt et al. J Antimicrob Chemother. 1997;39:235-240.
- https://doi.org/10.1093/jac/39.2.235
Rifampin for treatment of orthopedic implant infections (randomized controlled)
- Zimmerli et al. JAMA 1998. 279;1537-1341.
- https://doi.org/10.1001/jama.279.19.1537
Switch to PO = >4 weeks of IV for S. aureus OM, better with rifampin either with IV or PO
- Daver et al. J Infect 2007:54;539-544.
- https://doi.org/10.1016/j.jinf.2006.11.011
hVISA MRSA in IE was fairly common
- Bae et al. J Infect Dis. 2009;200(9):1355-1366.
- https://doi.org/10.1086/606027
Mortality was higher in S. aureus PVIE treated medically compared to surgically, except no difference in patients <50y
- Sohail et al. Am J Med. 2006;119(2):147-154.
- https://doi.org/10.1016/j.amjmed.2005.09.037
PO FQ + rifampin = IV for S. aureus infections
- Schrenzel et al. Clin Infect Dis 2004;39(9):1285-1292.
- https://doi.org/10.1086/424506
Vancomycin was superior to TMP-SMX in treating S. aureus infections (including bacteremia) in PWID, but all failures were in MSSA
- Markowitz et al. Ann Intern Med. 1992;117(5):390-398.
- https://doi.org/10.7326/0003-4819-117-5-390
Vancomycin was superior to TMP-SMX in treating severe MRSA infection, especially in bacteremia
- Paul et al. BMJ. 2015;350:h2219.
- https://doi.org/10.1136/bmj.h2219
Linezolid was noninferior to vancomycin for hte treatment of MRSA infections
- Stevens et al. Clin Infect Dis. 2002;34(11):1481-1490.
- https://doi.org/10.1086/340353
Linezolid = vancomycin for treatment of MRSA infections and may be more effective in achieving microbiolgical eradication
- Kohno et al. J Antimicrob Chemother. 2007;60(6):1361-1369.
- https://doi.org/10.1093/jac/dkm369
Linezolid = vancomycin for treatment of cSSTI caused by MRSA
- Itani et al. Am J Surg. 2010;199(6):804-816.
- https://doi.org/10.1016/j.amjsurg.2009.08.045
Clindamycin failed for SA endocarditis and led to development of resistance
- Watanakunakorn et al. Am J Med. 1976;60:419-425.
- https://doi.org/10.1016/0002-9343(76)90758-0
Rifampicin in treatment of osteoarticular infections
- Cluzel et al. J Antimicrob Chemother. 1984;13(Suppl. C):23-29.
- https://doi.org/10.1093/jac/13.suppl_c.23
Case report of imipenem/fosfomycin combination for refractory MRSAB and spinal abscess
- Sakoulas. Antimicrob Agents Chemother. 2020;AAC.02039-20.
- https://doi.org/10.1128/AAC.02039-20
S. aureus and coagulation system
- Peetermans et al. Semin Thromb Hemost. 2015;41(4):433-444.
- https://doi.org/10.1055/s-0035-1549849
S. aureus, master manipulator of the coagulation system
- Liesenborghs et al. J Thromb Haemost 2018;16:441-454.
- https://doi.org/10.1111/jth.13928
Outbreak of linezolid-resistant MRSA, which is very rare, in an ICU that used linezolid heavily
- Sanchez Garcia et al. JAMA. 2010;303(22):2260-2264.
- https://doi.org/10.1001/jama.2010.757
Case series of 10 PWID with right-sided S. aureus IE who were successfully treated with oral cipro + rifampin
- Dworkin et al. Lancet. 1989;2(8671):1071-1073.
- https://doi.org/10.1016/s0140-6736(89)91083-0
Comparing virulence and resistance of varieties of S. aureus
MedTweetorial: #Tweetorial
— MedTweetorials (@MedTweetorials) January 10, 2020
Author: @tony_breu
Type: #Pathophysiology
Specialty: #Nephrology #Renal #Neph
Topics: #MRSA #MSSA #StaphAureus #Staph https://t.co/6ck2L9CfUI
Postpartum Staph toxic shock syndrome
https://twitter.com/MayoClinicINFD/status/1328185662835666944?s=20
MRSA nasal screening had very high NPV for pneumonia
- Parente et al. Clin Infect Dis 2018; 67:1–7.
- https://doi.org/10.1093/cid/ciy024
MRSA nasal screening had very high NPV for pneumonia
- Dangerfield et al. Antimicrob Agents Chemother. 2014;58(2):859-64.
- https://doi.org/10.1128/AAC.01805-13
MRSA nasal screening had very high NPV for pneumonia
- Johnson et al. Perm J. Winter 2015;19(1):34-6.
- https://doi.org/10.7812/TPP/14-101
MRSA nasal screening had very high NPV for pneumonia
- Giancola et al. Diagn Microbiol Infect Dis. 2016;86(3):307-310.
- https://doi.org/10.1016/j.diagmicrobio.2016.08.011
MRSA nasal screening had very high NPV for nosocomial pneumonia
- Smith et al. J Crit Care. 2017;38:168-171.
- https://doi.org/10.1016/j.jcrc.2016.11.008
MSSA nasal swabs had a high PPV and NPV for wound infections in the ED
- Acquisto et al. Emerg Med J. 2018;35(6):357-360.
- https://doi.org/10.1136/emermed-2017-206843
MRSA nasal swabs had very high NPVs for multiple infections; huge study
- Mergenhagan et al. Clin Infect Dis 2020;71(5):1142-1148.
- https://doi.org/10.1093/cid/ciz974
Let us know in the comments if you have any papers you’d like to add/remove!